INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51601, 14761, 'Fesoterodine', 'Urinary Retention', 'The use of fesoterodine is contraindicated in patients with urinary retention.  Fesoterodine is a competitive muscarinic receptor antagonist and exerts direct antispasmodic effects on smooth muscles.  Caution is advised even when using this agent in patients with clinically significant bladder outlet obstruction because of the risk of urinary retention.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51602, 20038, 'Fesoterodine', 'Urinary Retention', 'The use of fesoterodine is contraindicated in patients with urinary retention.  Fesoterodine is a competitive muscarinic receptor antagonist and exerts direct antispasmodic effects on smooth muscles.  Caution is advised even when using this agent in patients with clinically significant bladder outlet obstruction because of the risk of urinary retention.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51603, 20039, 'Fesoterodine', 'Urinary Retention', 'The use of fesoterodine is contraindicated in patients with urinary retention.  Fesoterodine is a competitive muscarinic receptor antagonist and exerts direct antispasmodic effects on smooth muscles.  Caution is advised even when using this agent in patients with clinically significant bladder outlet obstruction because of the risk of urinary retention.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51604, 14760, 'Fesoterodine', 'Liver Diseases', 'The use of fesoterodine has not been studied in patients with severe hepatic impairment and therefore is not recommended for use in this patient population.  No dose adjustment is recommended in patients with mild or moderate hepatic impairment.  Use caution when using this agent in patients with severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51605, 14761, 'Fesoterodine', 'Liver Diseases', 'The use of fesoterodine has not been studied in patients with severe hepatic impairment and therefore is not recommended for use in this patient population.  No dose adjustment is recommended in patients with mild or moderate hepatic impairment.  Use caution when using this agent in patients with severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51606, 20038, 'Fesoterodine', 'Liver Diseases', 'The use of fesoterodine has not been studied in patients with severe hepatic impairment and therefore is not recommended for use in this patient population.  No dose adjustment is recommended in patients with mild or moderate hepatic impairment.  Use caution when using this agent in patients with severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51607, 20039, 'Fesoterodine', 'Liver Diseases', 'The use of fesoterodine has not been studied in patients with severe hepatic impairment and therefore is not recommended for use in this patient population.  No dose adjustment is recommended in patients with mild or moderate hepatic impairment.  Use caution when using this agent in patients with severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51608, 14760, 'Fesoterodine', 'Myasthenia Gravis', 'Fesoterodine is a competitive muscarinic receptor antagonist.  Fesoterodine should be used with caution in patients with myasthenia gravis, a disease characterized by decreased cholinergic activity at the neuromuscular junction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51609, 14761, 'Fesoterodine', 'Myasthenia Gravis', 'Fesoterodine is a competitive muscarinic receptor antagonist.  Fesoterodine should be used with caution in patients with myasthenia gravis, a disease characterized by decreased cholinergic activity at the neuromuscular junction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51610, 20038, 'Fesoterodine', 'Myasthenia Gravis', 'Fesoterodine is a competitive muscarinic receptor antagonist.  Fesoterodine should be used with caution in patients with myasthenia gravis, a disease characterized by decreased cholinergic activity at the neuromuscular junction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51611, 20039, 'Fesoterodine', 'Myasthenia Gravis', 'Fesoterodine is a competitive muscarinic receptor antagonist.  Fesoterodine should be used with caution in patients with myasthenia gravis, a disease characterized by decreased cholinergic activity at the neuromuscular junction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51612, 14760, 'Fesoterodine', 'Kidney Diseases', 'Doses of fesoterodine fumarate greater than 4 mg are not recommended in patients with severe renal impairment.  No dose adjustment is recommended in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51613, 14761, 'Fesoterodine', 'Kidney Diseases', 'Doses of fesoterodine fumarate greater than 4 mg are not recommended in patients with severe renal impairment.  No dose adjustment is recommended in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51614, 20038, 'Fesoterodine', 'Kidney Diseases', 'Doses of fesoterodine fumarate greater than 4 mg are not recommended in patients with severe renal impairment.  No dose adjustment is recommended in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51615, 20039, 'Fesoterodine', 'Kidney Diseases', 'Doses of fesoterodine fumarate greater than 4 mg are not recommended in patients with severe renal impairment.  No dose adjustment is recommended in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51616, 0, 'Flecainide', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51617, 0, 'Flecainide', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51618, 0, 'Flecainide', 'Sick Sinus Syndrome', 'The use of flecainide is contraindicated in patients with cardiogenic shock, second- or third-degree AV block or right bundle-branch block when associated with a left hemiblock(bifascicular block) in the absence of a functional artificial pacemaker, or congenital QT prolongation.  Therapy with flecainide should be administered with extreme caution in patients with sick sinus syndrome or bradycardia-tachycardia syndrome due to the risk of sinus bradycardia, pause or arrest.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51619, 0, 'Flecainide', 'Water-Electrolyte Imbalance', 'Electrolyte imbalance can alter the therapeutic effectiveness of antiarrhythmic agents.  Hypokalemia and hypomagnesemia can reduce the effectiveness of antiarrhythmic agents.  In some cases, these disorders can exaggerate the degree of QTc prolongation and increase the potential for torsade de pointes.  Hyperkalemia can potentiate the toxic effects of antiarrhythmic agents.  Electrolyte imbalance should be corrected prior to initiating antiarrhythmic therapy.  Clinical monitoring of cardiac function and electrolyte concentrations is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51620, 0, 'Flecainide', 'Liver Diseases', 'Since flecainide elimination from plasma can be markedly slower in patients with significant hepatic impairment, flecainide should not be used in such patients unless the potential benefits clearly outweigh the risks.  If used, frequent and early plasma level monitoring is required to guide dosage.  Additionally, dosage increases should be made very cautiously when plasma levels have plateaued (after more than four days).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51621, 0, 'Flecainide', 'Kidney Diseases', 'Flecainide is primarily eliminated by the kidney.  Approximately 30% (10% to 50%) of flecainide is excreted in the urine unchanged.  The serum concentration of flecainide is increased and the half-life prolonged in patients with renal impairment.  Rare conditions such as a strict vegetarian diet or renal tubular acidosis that significantly increase the urinary pH slow the urinary elimination of flecainide.  Adjustment of dosage is necessary and modification should be based on the degree of renal impairment.  Clinical monitoring of cardiac function (ECG) and renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51622, 13308, 'Filgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51623, 19035, 'Filgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51624, 19670, 'Filgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51625, 21172, 'Filgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51626, 23445, 'Filgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51627, 23641, 'Filgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51628, 23642, 'Filgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51629, 29848, 'Filgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51630, 29849, 'Filgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51631, 13308, 'Filgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51632, 19035, 'Filgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51633, 19670, 'Filgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51634, 21172, 'Filgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51635, 23445, 'Filgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51636, 23641, 'Filgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51637, 23642, 'Filgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51638, 29848, 'Filgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51639, 29849, 'Filgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51640, 13308, 'Filgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51641, 19035, 'Filgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51642, 19670, 'Filgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51643, 21172, 'Filgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51644, 23445, 'Filgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51645, 23641, 'Filgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51646, 23642, 'Filgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51647, 29848, 'Filgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51648, 29849, 'Filgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51649, 13308, 'Filgrastim', 'Sepsis', 'When filgrastim is used in septic patients, clinicians should be alerted to the theoretical possibility of adult respiratory distress syndrome, which may occur as a result of the influx of neutrophils at the site of inflammation.  Monitoring of respiratory status may be appropriate in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51650, 19035, 'Filgrastim', 'Sepsis', 'When filgrastim is used in septic patients, clinicians should be alerted to the theoretical possibility of adult respiratory distress syndrome, which may occur as a result of the influx of neutrophils at the site of inflammation.  Monitoring of respiratory status may be appropriate in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51651, 19670, 'Filgrastim', 'Sepsis', 'When filgrastim is used in septic patients, clinicians should be alerted to the theoretical possibility of adult respiratory distress syndrome, which may occur as a result of the influx of neutrophils at the site of inflammation.  Monitoring of respiratory status may be appropriate in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51652, 21172, 'Filgrastim', 'Sepsis', 'When filgrastim is used in septic patients, clinicians should be alerted to the theoretical possibility of adult respiratory distress syndrome, which may occur as a result of the influx of neutrophils at the site of inflammation.  Monitoring of respiratory status may be appropriate in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51653, 23445, 'Filgrastim', 'Sepsis', 'When filgrastim is used in septic patients, clinicians should be alerted to the theoretical possibility of adult respiratory distress syndrome, which may occur as a result of the influx of neutrophils at the site of inflammation.  Monitoring of respiratory status may be appropriate in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51654, 23641, 'Filgrastim', 'Sepsis', 'When filgrastim is used in septic patients, clinicians should be alerted to the theoretical possibility of adult respiratory distress syndrome, which may occur as a result of the influx of neutrophils at the site of inflammation.  Monitoring of respiratory status may be appropriate in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51655, 23642, 'Filgrastim', 'Sepsis', 'When filgrastim is used in septic patients, clinicians should be alerted to the theoretical possibility of adult respiratory distress syndrome, which may occur as a result of the influx of neutrophils at the site of inflammation.  Monitoring of respiratory status may be appropriate in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51656, 29848, 'Filgrastim', 'Sepsis', 'When filgrastim is used in septic patients, clinicians should be alerted to the theoretical possibility of adult respiratory distress syndrome, which may occur as a result of the influx of neutrophils at the site of inflammation.  Monitoring of respiratory status may be appropriate in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51657, 29849, 'Filgrastim', 'Sepsis', 'When filgrastim is used in septic patients, clinicians should be alerted to the theoretical possibility of adult respiratory distress syndrome, which may occur as a result of the influx of neutrophils at the site of inflammation.  Monitoring of respiratory status may be appropriate in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51658, 13308, 'Filgrastim', 'Thrombocytopenia', 'Filgrastim may occasionally lower platelet counts.  Thrombocytopenia has been reported, although most often the effects are mild or moderate and not associated with serious hemorrhagic sequelae.  Nevertheless, therapy with filgrastim should be administered cautiously in patients with preexisting thrombocytopenia.  Frequent blood counts are recommended, and the dosage of filgrastim adjusted if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51659, 19035, 'Filgrastim', 'Thrombocytopenia', 'Filgrastim may occasionally lower platelet counts.  Thrombocytopenia has been reported, although most often the effects are mild or moderate and not associated with serious hemorrhagic sequelae.  Nevertheless, therapy with filgrastim should be administered cautiously in patients with preexisting thrombocytopenia.  Frequent blood counts are recommended, and the dosage of filgrastim adjusted if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51660, 19670, 'Filgrastim', 'Thrombocytopenia', 'Filgrastim may occasionally lower platelet counts.  Thrombocytopenia has been reported, although most often the effects are mild or moderate and not associated with serious hemorrhagic sequelae.  Nevertheless, therapy with filgrastim should be administered cautiously in patients with preexisting thrombocytopenia.  Frequent blood counts are recommended, and the dosage of filgrastim adjusted if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51661, 21172, 'Filgrastim', 'Thrombocytopenia', 'Filgrastim may occasionally lower platelet counts.  Thrombocytopenia has been reported, although most often the effects are mild or moderate and not associated with serious hemorrhagic sequelae.  Nevertheless, therapy with filgrastim should be administered cautiously in patients with preexisting thrombocytopenia.  Frequent blood counts are recommended, and the dosage of filgrastim adjusted if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51662, 23445, 'Filgrastim', 'Thrombocytopenia', 'Filgrastim may occasionally lower platelet counts.  Thrombocytopenia has been reported, although most often the effects are mild or moderate and not associated with serious hemorrhagic sequelae.  Nevertheless, therapy with filgrastim should be administered cautiously in patients with preexisting thrombocytopenia.  Frequent blood counts are recommended, and the dosage of filgrastim adjusted if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51663, 23641, 'Filgrastim', 'Thrombocytopenia', 'Filgrastim may occasionally lower platelet counts.  Thrombocytopenia has been reported, although most often the effects are mild or moderate and not associated with serious hemorrhagic sequelae.  Nevertheless, therapy with filgrastim should be administered cautiously in patients with preexisting thrombocytopenia.  Frequent blood counts are recommended, and the dosage of filgrastim adjusted if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51664, 23642, 'Filgrastim', 'Thrombocytopenia', 'Filgrastim may occasionally lower platelet counts.  Thrombocytopenia has been reported, although most often the effects are mild or moderate and not associated with serious hemorrhagic sequelae.  Nevertheless, therapy with filgrastim should be administered cautiously in patients with preexisting thrombocytopenia.  Frequent blood counts are recommended, and the dosage of filgrastim adjusted if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51665, 29848, 'Filgrastim', 'Thrombocytopenia', 'Filgrastim may occasionally lower platelet counts.  Thrombocytopenia has been reported, although most often the effects are mild or moderate and not associated with serious hemorrhagic sequelae.  Nevertheless, therapy with filgrastim should be administered cautiously in patients with preexisting thrombocytopenia.  Frequent blood counts are recommended, and the dosage of filgrastim adjusted if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51666, 29849, 'Filgrastim', 'Thrombocytopenia', 'Filgrastim may occasionally lower platelet counts.  Thrombocytopenia has been reported, although most often the effects are mild or moderate and not associated with serious hemorrhagic sequelae.  Nevertheless, therapy with filgrastim should be administered cautiously in patients with preexisting thrombocytopenia.  Frequent blood counts are recommended, and the dosage of filgrastim adjusted if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51667, 13308, 'Filgrastim', 'Anemia, Sickle Cell', 'Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products.  Consider the potential risks and benefits prior to initiating therapy in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51668, 19035, 'Filgrastim', 'Anemia, Sickle Cell', 'Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products.  Consider the potential risks and benefits prior to initiating therapy in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51669, 19670, 'Filgrastim', 'Anemia, Sickle Cell', 'Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products.  Consider the potential risks and benefits prior to initiating therapy in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51670, 21172, 'Filgrastim', 'Anemia, Sickle Cell', 'Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products.  Consider the potential risks and benefits prior to initiating therapy in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51671, 23445, 'Filgrastim', 'Anemia, Sickle Cell', 'Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products.  Consider the potential risks and benefits prior to initiating therapy in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51672, 23641, 'Filgrastim', 'Anemia, Sickle Cell', 'Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products.  Consider the potential risks and benefits prior to initiating therapy in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51673, 23642, 'Filgrastim', 'Anemia, Sickle Cell', 'Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products.  Consider the potential risks and benefits prior to initiating therapy in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51674, 29848, 'Filgrastim', 'Anemia, Sickle Cell', 'Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products.  Consider the potential risks and benefits prior to initiating therapy in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51675, 29849, 'Filgrastim', 'Anemia, Sickle Cell', 'Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products.  Consider the potential risks and benefits prior to initiating therapy in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51676, 13308, 'Filgrastim', 'Neoplasms', 'Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51677, 19035, 'Filgrastim', 'Neoplasms', 'Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51678, 19670, 'Filgrastim', 'Neoplasms', 'Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51679, 21172, 'Filgrastim', 'Neoplasms', 'Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51680, 23445, 'Filgrastim', 'Neoplasms', 'Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51681, 23641, 'Filgrastim', 'Neoplasms', 'Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51682, 23642, 'Filgrastim', 'Neoplasms', 'Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51683, 29848, 'Filgrastim', 'Neoplasms', 'Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51684, 29849, 'Filgrastim', 'Neoplasms', 'Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51685, 24890, 'Aminolevulinic acid (topical)', 'Porphyrias', 'Photoactivation following topical application of aminolevulinic acid topical gel occurs when aminolevulinic acid (prodrug) is metabolized to protoporphyrin IX, a photoactive compound which accumulates in the skin.  Therapy with aminolevulinic acid topical gel increases photosensitivity and it may cause uncontrolled phototoxic effects.  Its use in contraindicated in patients with porphyria or photodermatoses.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51686, 24890, 'Aminolevulinic acid (topical)', 'Hemorrhage', 'The use of aminolevulinic acid topical gel increases the risk of bleeding in patients with coagulation disorders.  Care should be exercised during lesion preparation to avoid bleeding.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51687, 5457, 'Flavoxate', 'Intestinal Obstruction', 'The use of flavoxate is contraindicated in patients with GI obstruction, ileus, atony, and obstructive uropathy.  Flavoxate exerts direct antispasmodic effects on smooth muscles and possesses weak anticholinergic activity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51688, 23407, 'Flavoxate', 'Intestinal Obstruction', 'The use of flavoxate is contraindicated in patients with GI obstruction, ileus, atony, and obstructive uropathy.  Flavoxate exerts direct antispasmodic effects on smooth muscles and possesses weak anticholinergic activity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51689, 5457, 'Flavoxate', 'Glaucoma, Angle-Closure', 'Flavoxate exerts mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow angle) glaucoma.  Therapy with flavoxate should be administered cautiously in patients with angle-closure glaucoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51690, 23407, 'Flavoxate', 'Glaucoma, Angle-Closure', 'Flavoxate exerts mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow angle) glaucoma.  Therapy with flavoxate should be administered cautiously in patients with angle-closure glaucoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51691, 291, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51692, 292, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51693, 293, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51694, 383, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51695, 384, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51696, 385, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51697, 4719, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51698, 4720, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51699, 4721, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51700, 4853, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
